Teduglutide
- Generic Name
- Teduglutide
- Brand Names
- Gattex, Revestive
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 197922-42-2
- Unique Ingredient Identifier
- 7M19191IKG
- Background
Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that teduglutide is longer acting than endogeno...
- Indication
Teduglutide is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.
- Associated Conditions
- Short Bowel Syndrome (SBS)
- Associated Therapies
- -
Pharmacokinetics (PK) of 20 mg Teduglutide in Participants With Moderately Impaired Hepatic Function Compared to Healthy Participants
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Shire
- Target Recruit Count
- 24
- Registration Number
- NCT00819468
- Locations
- 🇺🇸
University of Miami Clinical Pharmacology Unit, Miami, Florida, United States
Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2021-06-03
- Lead Sponsor
- Shire
- Target Recruit Count
- 86
- Registration Number
- NCT00798967
- Locations
- 🇺🇸
University of Pennslyvania, Philadelphia, Pennsylvania, United States
🇺🇸Scripps Clinic & Research Foundation, La Jolla, California, United States
🇫🇷Hôpital de l'Archet Pôle Digestif, Nice Cedex 3, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.